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chemotherapy treatment decision-making. Methods: We embedded the validated 
Decisional Conflict Scale (DCS) into our discrete choice experiment survey exam-
ining preferences for chemotherapy treatment in early BrCa. Of the 1004 general 
population participants, 200 completed the DCS before (DCS-1; no GEP test score 
in scenario) and after (DCS-2; GEP test score added to scenario) the discrete choice 
experiment. The 16-item DCS was scored from 0-100 with five subscores. Mean 
total and subscores, standard deviations and change in scores were calculated, with 
significance based on matched pairs t-tests (p< 0.05). We anticipated GEP would 
decrease decisional conflict in individuals unsure of their chemotherapy treat-
ment decision. Results: As anticipated, total score and all subscores (uncertainty, 
informed, values clarity, support, and effective decision) decreased significantly (all 
p< 0.05) in the group of respondents (n= 33) who indicated uncertainty about tak-
ing chemotherapy in DCS-1 but changed to no chemotherapy after receiving a GEP 
test score in DCS-2. In the group of respondents (n= 25) who indicated they would 
undergo chemotherapy in DCS-1 but changed to unsure in DCS-2, their effective 
decision subscore increase significantly (24.5 to 34.5, p< 0.05). In the overall sample 
(n= 200), total decisional conflict decreased from DCS-1 to DCS-2 by 0.5 (p= 0.3) and 
all subscores had non-significant decreases with the exception of effective deci-
sion, which had a non-significant increase. ConClusions: GEP influences chemo-
therapy treatment decisional conflict in individuals who are initially unsure in their 
treatment decision-making. However, we do not observe this effect in individuals 
who do not change their chemotherapy treatment decisions.
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objeCtives: In oncology, the impact of interventions on health-related quality of life 
(HRQL) is traditionally modelled based on disease progression status. The aim of this 
analysis was to assess if more meaningful patterns exist in HRQL data, based on other 
clinically important events that should be considered in modelling utility. Methods: 
HRQL data from the CA184-024 trial of ipilimumab plus dacarbazine in previously 
untreated patients with unresectable malignant melanoma were analysed. European 
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 
Core-30 (EORTC QLQ-C30) responses were mapped to a generic, preference-based 
measure (EORTC-8D) by means of a published and validated mapping algorithm. 
The utility observations available for each patient were used to examine the relation-
ships between HRQL and a number of disease- and time-based variables, including 
treatment effect, progression status and time to death, via a mixed effects regression 
model. Results: Progression status was found not to be significantly predictive of 
utility (p= 0.29). Of the variables considered, the strongest relationship was with time 
to death, the mixed effects model for which was significantly predictive of utility 
(p≤ 0.001). HRQL dropped as patients approached death; patients treated with ipili-
mumab had a utility of 0.86 if time to death was more than 1 year, which reduced to 
0.61 during the final month of life. The ipilimumab treatment variable was associated 
with a small negative coefficient (-0.02), accounting for the adverse event profile of the 
drug when added to dacarbazine (p= 0.06). ConClusions: Analysis of the CA184-024 
HRQL data showed that time to death rather than progression status was significantly 
predictive of utility. Hence, modellers should carefully examine primary data to deter-
mine if a time to event approach or a progression based approach is appropriate to 
model utility best reflecting the pathology of the disease.
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objeCtives: Rasch modelling theory and its extensions have become popular tools 
in assessing psychometric properties of patient-reportedoutcome (PRO) instru-
ments. Since the Rasch model assumes a unidimensional structure, it is important 
to assert that this assumption has not been violated. However, there has been much 
debate about using factor analysis as the first step to assess dimensionality or using 
the Rasch model directly to identify items not fitting the unidimensional model. 
This study uses simulated data to compare the two techniques to examine the uni-
dimensional assumptions.  Methods: Simulated data that represent a typical PRO 
instrument are generated based on the following variables: sample size (200 or 400), 
number of factors (1,2, or 3), and correlation among factors (0.4 or 0.7). Each simu-
lated PRO assessment contains 15 items with 5 response categories. Exploratory 
factor analysis is conducted, and the number of factors proposed by the results 
are noted. A Rasch model theory analysis is also conducted, and the number of 
mis-fit items is noted. The unidimensional test associated with Rasch model is also 
conducted. Results: Preliminary results suggest that when there is one dominant 
factor, the Rasch results identify the simulated factor and it becomes the underlying 
trait. Items not belonging to the dominant factor are flagged as mis-fit items or as 
forming secondary factors based on the unidimensional test. In situations where 
there is no dominant factor, factor analysis is able to identify separate factors, 
whereas the results are inconsistent using Rasch model. ConClusions: Rasch first 
or factor first? The preliminary findings suggest that, when there is prior knowledge 
of a dominant factor, Rasch modelling can be conducted first and will result in a 
unidimensional measure. When there is no prior knowledge of a dominant fac-
tor, then factor analysis should be conducted first to examine the dimensionality.
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(> 0.7) for the Physical domain, high (> 0.5) for the Total score and the Living domain 
and moderate (> 0.3) for the Cognition and Emotional domains. ConClusions: The 
BRAF-MDQ was completed well by participants, related to appropriate measures 
of disease severity, retained its factor structure, gave reproducible results and was 
responsive to clinical change, confirming its validity as a measure of RA fatigue.
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objeCtives: Patient-reported outcome (PRO) measures provide relevant information 
on how patients function and feel about their health. Such data are useful in clinical 
practice and registrational trials. Despite the importance of symptom assessment in 
CDAD, there is no validated PRO for Clostridium difficile-associated diarrhoea (CDAD). 
A qualitative research study was conducted to develop a CDAD PRO according to US 
FDA PRO guidelines. Methods: Content development comprised 2 study phases, 
with input from an advisory group of 6 CDAD experts in Europe and North America. 
Phase I elicited patients’ experiences of CDAD symptoms in open-ended discussions 
during telephone interviews. Supplementary interviews obtained nurses’ observa-
tions. A draft PRO was developed following demonstration of concept saturation. 
Readability and translatability were assessed. Phase II involved 2 rounds of patient 
interviews, with revision of the draft PRO after each round. All patients were ≥ 18 
years old, with confirmed CDAD. IRB approval and participant informed consent 
were obtained. Results: Phase I interviews included 18 patients and 6 nurses in 
the United States; 16 additional patients were interviewed in Phase II. Patients were 
representative of the general CDAD population, and diverse in age, gender, and disease 
severity. Concept saturation was reached in Phase I for spontaneously reported CDAD 
symptoms. Items were organised in a draft conceptual framework with 5 hypoth-
esised domains: diarrhoea, abdominal discomfort, tiredness, lightheadedness, and 
other symptoms. Phase II demonstrated initial content validity of the 13-item draft 
daily diary (CDAD-DaySyms™). Participants reported the questions were clear, rel-
evant, and comprehensive; were able to use the instructions to complete the diary 
correctly; and considered the 24-hour recall period appropriate. ConClusions: 
The CDAD-DaySyms™ captures symptoms relevant to CDAD patients, demonstrat-
ing initial content validity. To allow its use in clinical practice and CDAD clinical 
studies, final content and psychometric validity are being evaluated in 2 ongoing 
international clinical trials.
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objeCtives: In phase II studies, alirocumab, a PCSK9 inhibitor administered via sub-
cutaneous injection, demonstrated significant reduction in LDL-C levels. The objective 
of this study was to conduct qualitative research to explore the concept of treatment 
acceptance in patients receiving a subcutaneous injection to support the develop-
ment and testing of a patient-reported outcome measure, the Injection-Treatment 
Acceptance Questionnaire (I-TAQ). Methods: A literature review led to the targeting 
of ‘treatment acceptance’ as the measurement concept in preference to treatment 
satisfaction. Concepts generated from the literature and instrument review informed 
the drafting of 17 items in the I-TAQ; item wording was adapted from three validated 
instruments. Qualitative interviews were conducted among 29 US-English speaking 
patients participating in alirocumab’s phase III program who self-administered the 
treatment via autoinjector (n= 19) or pre-filled syringe (n= 10). First, concept elicitation 
(CE) questioning was used to elicit concepts relating to patients’ treatment experi-
ences and acceptance. The I-TAQ was then cognitively debriefed using “think-aloud” 
methods. Verbatim transcripts were analyzed using thematic analysis and Atlas. ti. 
Revisions were considered after each round of interviews. Results: Qualitative 
analysis of CE data indicated treatment acceptance to be high, with the following 
concepts identified as relevant: perceived efficacy, side effects, self-efficacy, conveni-
ence and overall acceptance. Ten (34%) patients reported an initial fear of needles, 
which subsided with no impact on discontinuation. Pain was not considered rel-
evant by patients, suggesting no pain associated with the injection. Five items were 
added following round 1 interviews, three were retained after round 2 testing and two 
were added at finalization, forming the conceptually comprehensive 22-item I-TAQ. 
Patients demonstrated good understanding of item wording, instructions, response 
scales and recall period. ConClusions: Successive rounds of interviews resulted in a 
treatment acceptance measure with strong content validity. Next steps are to psycho-
metrically validate the I-TAQ in a population with experience of taking alirocumab.
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objeCtives: Individuals with BrCa have high decisional conflict with respect to 
treatment decisions. GEP of tumours informs risk prediction, potentially affecting 
decisions about adjuvant chemotherapy in early BrCa, where only 15% will experi-
ence recurrence. We aimed to examine whether GEP reduces decisional conflict in 
